Literature DB >> 10092782

Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1.

N V Henriquez1, E Floettmann, M Salmon, M Rowe, A B Rickinson.   

Abstract

Ligation of CD40 on the surface of B cells induces multiple phenotypic effects, many of which are mimicked by the EBV latent membrane protein 1 (LMP1) through its interaction with downstream components of the CD40 signaling pathway. Because the effects of LMP1 have been most closely studied in human Burkitt Lymphoma (BL) cell lines retaining a tumor biopsy-like phenotype in vitro, we have examined the response of a panel of such lines to CD40 ligation. Two distinct patterns of response were observed that were unrelated to the surface level of CD40 or to the EBV genome status of the lines. Following exposure to either CD40-specific mAbs or the soluble trimeric ligand (sCD40L), high responder (HR) lines showed rapid aggregation, activation of NF-kappa B, up-regulation of cell surface markers ICAM-1/CD54 and Fas/CD95, and growth inhibition. Aggregation was seen at lower doses than those required to elicit the other effects. By contrast, low responder (LR) lines showed no detectable response to CD40 mAbs, while their responses to sCD40L were limited to activation of NF-kappa B and up-regulation of CD95 only. However, in transfection experiments, LMP1 uniformly induced the full spectrum of phenotypic effects in both HR and LR lines. We conclude that some BL cell lines show a highly restricted response to CD40 ligation but remain fully susceptible to LMP1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092782

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  Soluble factors produced by activated CD4+ T cells modulate EBV latency.

Authors:  Noémi Nagy; Mónika Adori; Abu Rasul; Frank Heuts; Daniel Salamon; Dorina Ujvári; Harsha S Madapura; Benjamin Leveau; George Klein; Eva Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

3.  EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.

Authors:  Sachin Gupta; James M Termini; Liguo Niu; Saravana K Kanagavelu; Helena Schmidtmayerova; Victoria Snarsky; Richard S Kornbluth; Geoffrey W Stone
Journal:  J Leukoc Biol       Date:  2011-05-17       Impact factor: 4.962

4.  CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion.

Authors:  N J Gallagher; A G Eliopoulos; A Agathangelo; J Oates; J Crocker; L S Young
Journal:  Mol Pathol       Date:  2002-04

5.  CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies.

Authors:  Daisuke Ito; Aric M Frantz; Christina Williams; Rachael Thomas; Robert C Burnett; Anne C Avery; Matthew Breen; Nicola J Mason; Timothy D O'Brien; Jaime F Modiano
Journal:  Leuk Lymphoma       Date:  2012-02-03

6.  Epstein-Barr virus encoded latent membrane protein 1 (LMP1) and TNF receptor associated factors (TRAF): colocalisation of LMP1 and TRAF1 in primary EBV infection and in EBV associated Hodgkin lymphoma.

Authors:  G Siegler; E Kremmer; R Gonnella; G Niedobitek
Journal:  Mol Pathol       Date:  2003-06

7.  Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes.

Authors:  Liliana Terrin; Jessica Dal Col; Enrica Rampazzo; Paola Zancai; Moreno Pedrotti; Grazia Ammirabile; Stefano Bergamin; Silvana Rizzo; Riccardo Dolcetti; Anita De Rossi
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

8.  Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis.

Authors:  Christophe Le Clorennec; Tan-Sothéa Ouk; Ibtissam Youlyouz-Marfak; Stéphanie Panteix; Catherine-Claude Martin; Julia Rastelli; Eric Adriaenssens; Ursula Zimber-Strobl; Jean Coll; Jean Feuillard; Chantal Jayat-Vignoles
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

9.  Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor.

Authors:  Brendan N D'Souza; Leonard C Edelstein; Pamela M Pegman; Sinéad M Smith; Sinéad T Loughran; Ann Clarke; Anja Mehl; Martin Rowe; Céline Gélinas; Dermot Walls
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas.

Authors:  Alexandra Schrader; Katharina Meyer; Frederike von Bonin; Martina Vockerodt; Neele Walther; Elisabeth Hand; Antje Ulrich; Kamila Matulewicz; Dido Lenze; Michael Hummel; Arnd Kieser; Michael Engelke; Lorenz Trümper; Dieter Kube
Journal:  Cell Commun Signal       Date:  2012-12-20       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.